背后的故事我们研发投资500亿美元

We believe the journey to discovering new medicines and better treatments starts in our labs. Our commitment to innovative science is a commitment to bring new and impactful products and treatments to patients and customers around the world. Since our inception as a company in 2013, we have invested almost $50 billion in the pursuit of developing world-class medicines with the goal of lessening the burden of illness on patients, their caregivers and the healthcare system. And many of our scientific breakthroughs have done just that.
\r\n

\r\n

New medicines aren’t discovered quickly or easily. Despite our best intentions, most new molecules never make it out of the lab, and it takes hard work and dedication to translate foundational science into a viable new medicine. And yet that journey – pushing an idea to a breakthrough – drives this company.

\r\n

Our pipeline is our future. It’s an engine that will drive us 5, 10 and 20 years from now. Here are four things you may not know about our R&D investment and how it can help patients in need of new and better treatments. 

\r\n"}}" id="text-a7b2a010cf" class="cmp-text">

我们相信旅途中发现新的药物和更好的治疗方法开始在我们的实验室。我们致力于创新的科学是一个致力于带来新的和有效的产品和治疗病人和世界各地的客户。自2013年开始作为一个公司,我们已经投资了近500亿美元的追求发展世界级的药物的目标减少疾病对患者的负担,他们的照顾者和医疗保健系统。和我们的许多科学突破。

新药发现不迅速和容易。尽管我们最好的意图,大多数新分子从来没有让它走出实验室,需要努力工作和奉献的基础科学转化为一个可行的新药。然而,这旅程——推动一个想法一个突破,推动本公司。

我们的管道是我们的未来。这是一个引擎,将推动我们5、10和20年后。这里有四件事情你可能不知道我们的研发投资以及它如何帮助病人需要新的和更好的治疗方法。

Some of the time, we are successful, and our R&D investment leads to a new medicine. But most of the time, we are not. It takes an average of 10 years and $2 to $3 billion to bring one new medicine to market. Less than 12 percent of new molecular entities that enter clinical trials eventually receive U.S. Food and Drug Administration approval.

\r\n

That doesn’t mean we give up.

\r\n

Take, for example, our commitment to neurological conditions: Alzheimer’s disease and Parkinson’s disease are the most common neurological disorders worldwide, with over 50 million people living with dementia and Alzheimer’s disease, and 10 million more with Parkinson’s. While there are treatments to help reduce symptoms, there are no treatments available to help stop or reverse progression.

\r\n

Given the enormous unmet need in Alzheimer’s in particular, we remain committed to finding disease-modifying therapies. We have several additional programs that are either in the clinic today or are in preclinical development, including an asset for patients with advanced Parkinson’s disease.

\r\n"}}" id="text-4d26187ca4" class="cmp-text">

有些时候,我们是成功的,我们的研发投资导致一种新药。但是大多数时候,我们不是。平均需要10年和2到30亿美元给市场带来一个新药。不到12%的新分子实体进入临床试验最终获得美国食品和药物管理局的批准。

这并不意味着我们放弃。

举个例子,我们致力于神经条件:阿尔茨海默病和帕金森病是最常见的神经系统疾病在世界范围内,有超过5000万人患有痴呆和阿尔茨海默氏症,并与帕金森1000万多。虽然有治疗有助于减少症状,没有治疗可以帮助阻止或逆转恶化。

考虑到巨大的未满足的需求特别是在阿尔茨海默氏症,我们仍致力于寻找疾病修饰治疗。我们有几个额外的项目,今天在诊所或在临床前开发,包括晚期帕金森症患者的资产。狗万正网地址

In 2013 when we became an independent company, our R&D investment was $2.8 billion, and that number has continued to grow – leading to a $5.8 billion annual investment in 2020. Many of the top scientists in their fields come to AbbVie because of this continued and growing investment. Our focus on science has attracted leading scientific talent, including a member of the team that first mapped the human genome and a scientist who was one of the first to use genome sequencing to diagnose, treat and cure a patient who was suffering from a mysterious intestinal disease.

\r\n

These influential leaders in their field come to AbbVie to work on discovering and developing new medicines. They come because of our dedication to continuous investment in R&D and because they want to be part of a team that works to change the lives of whole groups of patients.

\r\n"}}" id="text-535e05ba59" class="cmp-text">

2013年,当我们成为一个独立的公司,我们的研发投资是28亿美元,这个数字一直在增长,导致每年58亿美元的投资在2020年。许多顶级科学家在他们的领域来AbbVie因为这个持续和不断增长的投资。我们专注于科学吸引了领先的科学人才,包括团队的一名成员,首先绘制人类基因组,科学家是第一个使用基因组测序诊断,治疗,治愈的病人患有一种神秘的肠道疾病。

这些有影响力的领导人在他们的领域来AbbVie致力于发现和开发新药物。他们会因为我们的持续投资研发和奉献精神,因为他们想成为团队的一部分,改变整个组患者的生命。

Revenue generated by our on-market medicines supports our ongoing R&D investment, funding future treatments and cures. And our R&D work does not end when a medicine is approved. We spend years monitoring thousands of patients that are taking a newly approved medicine to better understand the risks and potential benefits over time, and to explore whether additional groups of patients may benefit from the science behind the medicine. Throughout the development process and after a medicine is on the market, we continually look for and research additional areas where it can show benefit.

\r\n

Data from on-market studies often leads to the discovery that one medicine can help additional patients with other similar diseases or that a medicine can help patients suffering from rare diseases. Although diseases may only impact a relatively small number of patients, their impact on public health is far-reaching, and we believe our science can help these patients.

\r\n

For example, we are currently evaluating investigational compounds in early clinical phases for a triple combination therapy that could help cystic fibrosis (CF) patients. CF is a rare, life-threatening, genetic disease that affects between 70,000 and 100,000 patients worldwide. In the U.S. and U.K., average life expectancy is 35 to 40 years old and currently there is no cure.

\r\n

Biopharmaceutical R&D is a lengthy, challenging and expensive pursuit. But we are inspired by that goal of helping patients and changing lives. So, we keep improving and investing, and revenue generated from on-market medicines enables us to fund the innovative R&D that will discover future treatments.

\r\n"}}" id="text-a26dd2f195" class="cmp-text">

收入由我们市场的药物支持正在进行的研发投资,融资未来的治疗和治愈。和我们的研发工作不能当药物被批准而结束。我们花年监测成千上万的病人服用一种新批准药物更好地理解风险和潜在的好处,并探讨是否附加组的患者可能受益于背后的科学医学。在整个开发过程和医药市场上后,狗万正网地址我们不断的寻找和研究其他领域可以显示的好处。

市场研究数据往往能发现那个药可以帮助更多的病人与其他类似的疾病或药物可以帮助病人患有罕见疾病。尽管疾病可能只影响相对较小的患者数量,它们对公共卫生的影响是深远的,我们相信科学可以帮助这些病人。manbet体育网址

例如,我们正在评估临床实验的化合物在早期临床阶段三联合治疗能够帮助囊性纤维化(CF)的病人。CF是一种罕见的、危及生命的、遗传的疾病,在全世界影响病人在70000年到100000年之间。在美国和英国,平均寿命是35 - 40岁,目前没有治愈。

生物制药研发是一个漫长的、挑战性和昂贵的追求。但我们受到启发,帮助病人和改变生活的目标。我们精益求精和投资,和收入来自市场的药物能使我们基金创新研发,将发现未来的治疗。

Since 2013, our pipeline of investigational medicines has only grown. When we started on our journey as an independent company, we were known as an immunology company. Today, we are market leaders in immunology, hematologic oncology, aesthetics, neuroscience and eye care. Our investment in R&D has led to life-changing medicines, including cures for some fatal diseases like hepatitis C, improvements in the treatment of chronic autoimmune diseases, and medicines that significantly alter the progression for certain cancers.

\r\n

That is because we have built a company focused on harnessing innovation for patients, leading to one of the strongest and most diverse pipelines in our industry. We have had 19 major product or indication approvals since 2013. We have also more than tripled the number of programs in clinical development. We anticipate 12 new products or indications over the next two years.

\r\n"}}" id="text-ac1da19372" class="cmp-text">

自2013年以来,我们的管道临床实验的药物仍有增无减。当我们开始我们的旅行作为一个独立的公司,我们公司被称为一个免疫学。今天,我们是市场领导者在免疫学、血液肿瘤、美学、神经科学和眼睛护理。我们在研发的投资导致了改变人生的药品,包括治疗一些致命的疾病如丙型肝炎,改善慢性自身免疫性疾病的治疗,药物,显著改变了某些癌症的发展。

这是因为我们已经建立了一个公司专注于利用创新对病人,导致最强大的和最多样化的管道之一在我们的行业。我们有19个主要产品或指示批准自2013年以来。我们还增加了两倍多的数量在临床开发项目。狗万正网地址我们预计12个新产品或在未来两年。

When people think of large pharmaceutical companies, they don’t often think of biochemists staying late to get lab results or data scientists poring over real time data on patient outcomes. But they should.

\r\n

Because it’s science – and the billions we have invested in our science – that drives this company. There are scientists in our labs today who come to work every day with one goal: to help patients. Many work years to advance a molecule to the next stage of clinical development. They are working to get patients back to their lives, back to their families. I’m tremendously proud that AbbVie has helped millions of patients, but I’m even prouder of our potential and of what we can do for the millions who still need new and better treatments. The innovation in our labs has always connected us to patients.

\r\n

And it always will.

\r\n"}}" id="text-5f3a863b7d" class="cmp-text">

当人们想到大型制药公司,他们不常想到的生化学家晚得到实验室的结果或数据科学家们仔细研究了实时数据对病人的结果。但他们应该。

因为它是科学——数十亿我们投资于科学,推动本公司。manbet体育网址今天有我们实验室的科学家每天来上班有一个目标:帮助病人。许多工作年进分子临床发展的下一阶段。狗万正网地址他们正在努力让病人回到他们的生活,回到他们的家庭。我非常自豪AbbVie已经帮助成千上万的病人,但我更自豪我们的潜力,我们能做的数百万人仍然需要新的和更好的治疗方法。创新在我们的实验室一直连接我们的病人。

它一直会是这样。